[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100364392":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":31,"locations":39,"responsibleParty":65,"collaborators":19,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":19,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":19,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":58,"whyStopped":19,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Phenotyping","All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.\n\nThey will also undergo a whole body DXA (intervention) during the study day.",[12,13],"Other: 75g glucose beverage (Glucola, Trutol, or similar brand)","Other: DXA, whole body",[15,20],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"75g glucose beverage (Glucola, Trutol, or similar brand)","Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.",[9],null,{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":19},"DXA, whole body","Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.",[9],[25,28],{"name":26,"affiliation":5,"role":27},"Jessica R Wilson, MD, MS","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":27},"Lorraine Levitt Katz, MD","Children's Hospital of Philadelphia",[32,36],{"name":26,"role":33,"phone":34,"phoneExt":19,"email":35},"CONTACT","215 898-3389","jessica.wilson3@uphs.upenn.edu",{"name":37,"role":33,"phone":19,"phoneExt":19,"email":38},"Esther Oyerinde","esther.oyerinde@pennmedicine.upenn.edu",[40,57],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Childrens Hospital of Philadelphia","NOT_YET_RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-75.16362,39.95238,{"lat":52,"lon":51},[55,56],{"name":26,"role":33,"phone":34,"phoneExt":19,"email":35},{"name":37,"role":33,"phone":19,"phoneExt":19,"email":38},{"facility":5,"status":58,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"RECRUITING",{"type":49,"coordinates":60},[51,52],{"lat":52,"lon":51},[63,64],{"name":26,"role":33,"phone":34,"phoneExt":19,"email":35},{"name":37,"role":33,"phone":19,"phoneExt":19,"email":38},{"type":27,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Jessica R.Wilson, MD, MS","Instructor in Medicine","100364392","phenotyping-genetic-risk-for-type-2-diabetes-100364392",false,"NCT04024631","Phenotyping Genetic Risk for Type 2 Diabetes","Phenotyping Children and Adults With Possible High or Low Genetic Risk for Type 2 Diabetes","Inclusion Criteria:\n\n* Age 10-70 years\n* Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research.\n* Adults with BMI 25kg\u002Fm2 or higher, children and adolescents with BMI 85th percentile or higher\n\nExclusion Criteria:\n\n* prior diagnosis of type 1, type 2, or secondary diabetes\n* use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication\n* acute illness that may impact insulin and glucose dynamics\n* pregnancy\n* hypothalamic obesity or related genetic disorder of metabolism\n* recent systemic chemotherapy use\n* gastrointestinal impairment or surgery that may impact absorption\n* anemia\n* major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult\n* inability to comply with study protocol",true,"ALL","10 Years","70 Years",{"count":80,"type":81},100,"ESTIMATED","INTERVENTIONAL",[84],"NA","This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.",[87,88],"Diabetes Mellitus, Type 2","Genetics",[90],"polygenic risk for type 2 diabetes","2025-09-03",{"date":93,"type":94},"2025-09-10","ACTUAL",{"date":96,"type":94},"2019-06-17",{"date":98,"type":81},"2026-06-30",{"name":5,"class":6},2]